NMN dosage is one of the most frequently asked questions in the NAD+ supplement space, and one of the least satisfyingly answered. The honest response — that no established optimal dose exists for longevity purposes in healthy humans — is accurate but not particularly useful when you are standing in front of a product offering 250 mg, 500 mg, and 1,000 mg options at meaningfully different price points.
What does exist is a body of human clinical trial data covering a range of doses, a set of community protocols that have emerged from researchers and practitioners working in this space, and enough mechanistic understanding to reason about dose in a principled way. This guide synthesizes all of that into practical guidance for choosing a starting dose, deciding when and how to increase it, and understanding what the available evidence does and does not support.
Contents
What Human Clinical Trials Tell Us About Dose
The most reliable anchor for NMN dosing decisions is the human clinical trial literature. These trials have tested a range of doses in different populations and measured both NAD+ elevation and downstream effects on health markers. The full picture of what those trials found is covered in the article on what human clinical trials on NMN actually show. The dosing-relevant highlights:
250 mg/day: The Igarashi et al. (2022) trial in NPJ Aging used 250 mg/day in older adults over 12 weeks and found significant NAD+ elevation alongside improvements in muscle function and a measure of biological age. This is among the most rigorous human trials to date and establishes 250 mg/day as a dose that produces meaningful NAD+ increases and measurable downstream effects in older adults.
300 mg/day: Used in several NR trials (NR and NMN are distinct precursors but inform dose reasoning for the class) and in some NMN studies. Consistently produces NAD+ elevation above baseline.
500 mg/day: A common midrange dose used in multiple trials. A study by Yoshino et al. (2021) in Science used 250 mg twice daily (500 mg total) in postmenopausal women with prediabetes and found improvements in muscle insulin sensitivity — one of the stronger functional outcomes in the human NMN literature to date.
1,000 mg/day: Used in trials examining metabolic, cardiovascular, and exercise performance outcomes. A trial by Yi et al. (2023) in GeroScience using 1,000 mg/day found improvements in muscle strength, endurance performance, and fatigue measures in older adults over 12 weeks. Safety was well-characterized at this dose across multiple trials with no concerning adverse effects identified.
1,200 mg/day: The highest dose examined in some trials. A safety and pharmacokinetics trial by Irie et al. (2020) in NPJ Aging found single doses up to 500 mg and multiple doses up to 1,200 mg/day were safe and well-tolerated in healthy adult men, with dose-dependent NAD+ elevation.
The pattern across these trials is consistent: NAD+ elevation occurs across the full dose range tested, with higher doses producing larger increases. Functional benefits have been demonstrated at doses from 250 mg to 1,000 mg/day. No dose within this range has produced clinically meaningful adverse effects in healthy adults.
Is There a Dose-Response Relationship?
Within the studied range, yes — higher NMN doses produce greater NAD+ elevation. Whether this linear dose-response relationship continues indefinitely or plateaus at some point is not fully characterized. There is likely a ceiling effect at some dose where additional NMN cannot meaningfully increase NAD+ synthesis because other factors become limiting — availability of ATP for the synthesis reaction, activity of downstream enzymes, or cellular demand for NAD+. Where that ceiling lies in humans is not established.
Importantly, greater NAD+ elevation does not automatically translate to proportionally greater functional benefits. Many of the downstream effects of elevated NAD+ are mediated through enzymes like sirtuins that have their own kinetics and limiting factors beyond NAD+ availability. Raising NAD+ from severely depleted levels to normal range likely produces larger benefits than raising it from normal to supraphysiological levels — a pattern consistent with the general principle that correcting a deficiency produces greater effects than augmenting an already adequate state.
This distinction matters practically because it suggests that the marginal benefit of going from 500 mg to 1,000 mg/day may be smaller than the benefit of going from 0 to 500 mg — and that people who are more deficient in NAD+ (typically older adults) may see larger absolute benefits from supplementation than younger, metabolically healthier individuals at equivalent doses.
Starting Dose: Where to Begin
For most adults beginning NMN supplementation, a starting dose of 250–500 mg/day is well-supported by the clinical evidence and represents a practical entry point.
Arguments for starting at 250 mg:
- Demonstrated efficacy in the Igarashi 2022 trial — this is not a trivially small dose
- Allows you to establish tolerability and any subjective response at a cost-effective level before committing to higher doses
- Appropriate for younger adults (under 50) with healthier baseline NAD+ levels, where the gap being corrected is smaller
Arguments for starting at 500 mg:
- More consistent with the dose range showing functional metabolic and performance benefits across multiple trials
- Used in the Yoshino 2021 trial showing muscle insulin sensitivity improvement — one of the most clinically meaningful NMN outcomes in human data
- More appropriate as a starting dose for adults over 50, where NAD+ decline is more pronounced
There is no strong argument for starting above 500 mg. The additional benefit of beginning at 1,000 mg versus working up to it over several weeks is unlikely to be meaningful, and beginning lower allows you to confirm tolerability and establish a baseline experience before increasing.
When and How to Increase Dose
After four to eight weeks at your starting dose, you can assess whether to increase. The decision framework is straightforward:
If your goal is general longevity support and your starting dose is producing subjectively noticeable effects (improved energy, better sleep, faster exercise recovery — acknowledging that many people notice nothing subjective regardless of dose), there may be no compelling reason to increase. Staying at 500 mg/day and directing budget toward other stack components has rational justification.
If your goal is to maximize NAD+ elevation in line with more aggressive longevity protocols, or if you are over 60 and want to address a more significant NAD+ deficit, moving to 750–1,000 mg/day is supported by the clinical evidence. The Sinclair-influenced protocol commonly referenced in longevity circles uses 1,000 mg/day, and this dose has the most clinical trial support for functional outcomes in older adults.
Increase gradually — adding 250 mg every two to four weeks rather than jumping directly to 1,000 mg — particularly if you are sensitive to supplements or have not established your response at lower doses.
Does Age Change the Right Dose?
Age is probably the most relevant individual factor in NMN dosing. NAD+ levels decline progressively with age — estimates suggest a 40–60% reduction between young adulthood and the sixth decade of life. The gap between a person’s current NAD+ level and the level associated with optimal cellular function is larger in a 65-year-old than in a 40-year-old, which means the older individual has more to gain from aggressive NAD+ repletion and more justification for higher doses.
A rough age-based dosing framework, consistent with community practice and the clinical evidence:
- Under 40: 250–500 mg/day. NAD+ decline is modest at this age; supplementation is more preventive than corrective. Lower doses are well-justified.
- 40–55: 500 mg/day as a reasonable standard dose. Meaningful NAD+ decline is occurring in this window, and 500 mg addresses it with good clinical support.
- 55–65: 500–750 mg/day. Declining NAD+ is more substantial, and the trials showing functional benefits in older adults generally used doses in this range or higher.
- Over 65: 750–1,000 mg/day. The most significant NAD+ deficit, and the age group where clinical trials have shown the most meaningful functional improvements. The higher end of the dose range is best supported for this population. The article on NMN for people over 60 covers additional considerations specific to this age group.
These are guidelines, not prescriptions. Individual variation in baseline NAD+ levels, genetics, lifestyle, and health status means the right dose for any individual may differ from these ranges. NAD+ testing before and after establishing a dose is the most direct way to calibrate — covered in the article on how to test your NAD+ levels.
Does Health Status or Goal Affect Dose?
Beyond age, several factors are worth considering when calibrating dose.
Metabolic health: People with insulin resistance, metabolic syndrome, or type 2 diabetes may benefit from doses at the higher end of the range given the established relationship between NAD+ and metabolic function. The Yoshino 2021 trial specifically studied women with prediabetes and found meaningful insulin sensitivity improvements at 500 mg/day — this is a population where NAD+ metabolism is already compromised and supplementation has more to correct.
Exercise and athletic performance: Some research suggests NMN may support exercise performance and recovery through mitochondrial and muscle function effects. The Yi 2023 trial found performance and endurance benefits at 1,000 mg/day in older adults. If exercise performance is a primary goal, doses toward the higher end of the range have more trial support for that specific outcome.
Cognitive goals: The relationship between NAD+ and brain health is an active area of research. The article on NAD+ and cognitive decline covers the mechanistic and emerging clinical evidence. No specific dose has been established for cognitive outcomes; general dosing guidance applies.
People with specific health conditions: If you have a significant health condition — particularly cancer history, given the theoretical concern about NMN and tumor growth discussed in the article on NMN and cancer — dosing decisions should involve a healthcare provider rather than self-directed escalation.
The Upper Limit: How Much Is Too Much?
No established upper safe limit for NMN has been defined in humans, and trials have not identified safety concerns at doses up to 1,200 mg/day in healthy adults. This does not mean higher doses are risk-free indefinitely — the safety database simply does not extend to very high doses over long time periods.
Practically speaking, doses above 1,000 mg/day have diminishing clinical justification given that the evidence for functional benefits is concentrated at 500–1,000 mg/day. Spending more to go higher is unlikely to produce proportionally greater benefit and is ahead of the evidence in a way that lower doses in the studied range are not. Most longevity-focused practitioners do not recommend above 1,000 mg/day without specific rationale.
The most common adverse effects at higher doses are GI-related: nausea, loose stools, or stomach discomfort. These typically resolve with dose reduction or taking NMN with food rather than on an empty stomach.
A Practical Summary
The dosing picture for NMN simplifies to a few clear guidelines:
- Start at 250–500 mg/day and establish tolerability before increasing
- 500 mg/day is a well-supported standard dose for most adults
- 750–1,000 mg/day is appropriate for adults over 55–60, those with significant metabolic concerns, or those following more aggressive longevity protocols
- Above 1,000 mg/day lacks meaningful additional clinical support and is not generally recommended
- Increase gradually; monitor for GI effects; adjust timing or food co-administration if needed
- NAD+ level testing is the most objective way to confirm your dose is producing the intended effect
Frequently Asked Questions
Should I take my full NMN dose at once or split it?
Most human trials have used once-daily dosing, and there is no strong clinical evidence that splitting the dose produces meaningfully better NAD+ elevation than a single daily dose. That said, NMN has a relatively short half-life in plasma, and some practitioners prefer splitting doses at higher amounts — for example, 500 mg in the morning and 500 mg at midday — on the basis that maintaining more consistent plasma NMN levels throughout the day may better support continuous NAD+ synthesis. Either approach is reasonable; once-daily morning dosing is simpler and well-supported by the trial evidence.
Does body weight affect how much NMN I should take?
Clinical trials have not used weight-based dosing, and no weight-adjusted dosing formula has been established for NMN. The trials showing benefits used fixed doses across participants with varying body weights. Weight-based adjustment is not the standard approach and is not necessary for most people. Very large individuals might reasonably consider the higher end of the dose range on general pharmacokinetic principles, but this is extrapolation rather than evidence.
What if I miss a dose?
Miss it and continue the next day at your normal dose — do not double up. NAD+ is not a compound where a single missed day produces a meaningful deficit given the cumulative nature of the supplementation effect over weeks and months. Consistency over time matters more than any individual dose.
Can I take more NMN when I feel I need an energy boost?
NMN is not acutely stimulating in the way that caffeine is, and taking extra doses when tired is unlikely to produce a noticeable immediate effect. The NAD+-elevating and energy-supporting effects of NMN operate through cellular mechanisms over longer time periods, not through acute stimulation. Using NMN as an on-demand energy supplement misunderstands how it works.